Cerebral Perfusion and Aortic Stiffness Are Independent Predictors of White Matter Brain Atrophy in Type 1 Diabetic Patients Assessed With Magnetic Resonance Imaging by van Elderen, Saskia G.C. et al.
Cerebral Perfusion and Aortic Stiffness
Are Independent Predictors of White
Matter Brain Atrophy in Type 1 Diabetic
Patients Assessed With Magnetic
Resonance Imaging




JEROEN VAN DER GROND, PHD
1
JOS J.M. WESTENBERG, PHD
1
LUCIA J.M. KROFT, MD
1
MARK A. VAN BUCHEM, MD
1
JOHANNES W.A. SMIT, MD
2
ALBERT DE ROOS, MD
1
OBJECTIVE—To identify vascular mechanisms of brain atrophy in type 1 diabetes mellitus
(DM) patients by investigating the relationship between brain volumes and cerebral perfusion
and aortic stiffness using magnetic resonance imaging (MRI).
RESEARCH DESIGN AND METHODS—Approval from the local institutional review
board was obtained, and patients gave informed consent. Fifty-one type 1 DM patients (30 men;
meanage44611years;meanDMduration23612years)and34age-andsex-matchedhealthy
control subjects were prospectively enrolled. Exclusion criteria comprised hypertension, stroke,
aortic disease, and standard MRI contraindications. White matter (WM) and gray matter (GM)
brain volumes, total cerebral blood ﬂow (tCBF), total brain perfusion, and aortic pulse wave
velocity (PWV) were assessed using MRI. Multivariable linear regression analysis was used for
statistics,withcovariatesage,sex,meanarterialpressure,BMI,smoking,heartrate,DMduration,
and HbA1c.






CONCLUSIONS—Type 1 DM patients without hypertension showed WM and GM volume
loss compared with control subjects concomitant with a relative increased brain perfusion. Total
CBFandstiffnessoftheaortaindependentlypredictedWMbrainatrophyintype1DM.Onlyage
predicted GM brain atrophy.
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I
n type 1 diabetes mellitus (DM) pa-
tients, early development of brain
atrophy (1,2), which may affect cogni-
tive functioning (3), has been demon-
strated. Multiple pathophysiological
mechanisms like repeated hypoglycemic
episodes (4), chronic hyperglycemia (5),
and alterations in insulin metabolism and
associated insulin use (6) are suggested to
be involved in the development of cere-
bral complications in type 1 DM. Al-
though cerebral atrophy is common in
neurodegenerative processes, decreased
brain volumes have been associated with
vascular risk factors (3,7), suggesting vas-
cular mechanisms contributing to the
development of brain atrophy. Indeed,
the hyperglycemic state of DM induces
structural changes and endothelial
dysfunction of the macro- and microvas-
culature (8). Impaired cerebrovascular
reactivity in type 1 DM has been demon-
strated recently (9), and cerebral perfu-
sion abnormalities have been found in
type 1 DM patients in earlier studies
(10). The cerebral circulation plays an
importantroleinthemaintenanceofneu-
ronal cell integrity, and therewith poten-
tially in the development of brain
atrophy.
Furthermore, arterial stiffening has
shown to occur in type 1 DM, being an
independent predictor of cardiovascular
outcome (11). The elastic aorta is the pre-
dominant site of pathologic arterial stiff-
ening. Aortic stiffening increases pulse
wave velocity (PWV) and pulse pressure
(PP), placing considerable pulsatile stress
on the peripheral circulation. The brain
is a high ﬂow organ and therewith partic-
ularly susceptible to pulsatile stress.
Therefore, it is conceivable that aortic
stiffness is contributing to the pathogen-
esis of brain atrophy in type 1 DM.
Although the associations between
type 1 DM and cerebral perfusion or
arterial stiffening have been described,
their relationship with brain volumes in
thispatientgroup,toinvestigate potential
vascular mechanisms causing brain atro-
phy, has not been assessed until now.
Quantitative measurements of brain
volumes can be accurately evaluated on
scans obtained by magnetic resonance
imaging (MRI) (12). MRI using phase-
contrast is a reliable method for estimat-
ing total cerebral blood ﬂow (tCBF) (13)
as well as for evaluating aortic stiffness by
means of PWV (14).
Accordingly, the purpose of the cur-
rent study was to identify potential un-
derlying vascular mechanisms of brain
atrophy in type 1 DM patients by in-
vestigating the relationship between
brain volumes and cerebral perfusion
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Between February 2008 and January
2010, a total of 51 consecutive type 1
DM patients from the local outpatient
clinic of the Leiden University Medical
Center and 34 age- and sex-matched
healthy control subjects recruited by ad-
vertisement in local newspapers partici-
pated in the study. Healthy control
subjects did not have a history or clinical
evidence of DM, hypertension, or cardio-
vascular disease. Exclusion criteria for all
participants included a clinical history or
diagnosis of hypertension according to
the guidelines of the European Society of
Cardiology, stroke, aortic valve stenosis,
or insufﬁciency as evaluated by means of
cardiac auscultation and velocity-encoded
MRI, Marfan syndrome, and standard MRI
contraindications like claustrophobia,
pacemaker, and metal implantations.
Information about type 1 DM and
healthy control characteristics was ob-
tained by standardized interviews and
physical and laboratory examinations.
Type 1 DM duration was estimated as the
time passed between the reported age of
diagnosis and the MRI examination. BMI
was calculated from body length and mass
at the time of MRI. Blood pressure and
heart rate were measured after MRI using a
semiautomated sphygmomanometer (Di-
namap, Critikon, Tampa, FL, validated to
ANSI/AAMI SP10 criteria). PP was deﬁned
as the difference between systolic and di-
astolic blood pressure. Mean arterial pres-
sure (MAP) was calculated by adding
diastolic blood pressure to one-third of
the PP. Smoking was deﬁned as non-
smoker or a current smoker. Retinopathy
was recognized on fundoscopy. Monoﬁla-
ment testing was used to diagnose periph-
eral neuropathies. Microalbuminuria was
deﬁned as 30–300 mg albumin/24-h urine
collection or microalbumuria/creatinine
ratio .2.5 mg/mmol for men or .3.5
mg/mmol for women. HbA1c in type 1
DM,fastingglucoseinhealthycontrolsub-
jects, high-density lipoprotein (HDL), total
cholesterol, triglycerides, and creatinine
were furthermore determined.
The study was approved by the local
medical ethics committee and conducted
according to the principles in the Decla-
ration of Helsinki. All study participants
signed informed consent.
MRI protocol
All brain examinations were performed
on a 3.0-Tesla MRI (Achieva; Philips Med-
icalSystems,Best,theNetherlands).Aortic
imaging was performed using 1.5-Tesla
MRI (NT 15 Gyroscan Intera; Philips
Medical Systems, Best, the Netherlands).
Brain MRI consisted of a three-
dimensional T1 sequence for brain vol-
ume assessment and a two-dimensional
phase contrastscan at thelevelofthe skull
baseforﬂowmeasurementsintheinternal
carotid arteries and basilar artery.
For the evaluation of white matter
(WM) and gray matter (GM) brain vol-
umes, the three-dimensional T1 image
(repetition time [TR] 9.8 ms, echo time
[TE] 4.6 ms, ﬂip angle [FA] 8°, ﬁeld of
view [FOV] 224 mm, 192 3 152 acqui-
sition matrix, 256 3 256 reconstruction
matrix,slicethickness1.2mm,120slices,
no slice gap) was obtained. Software
package SIENAX automatically segments
brain from nonbrain matter; calculates
white, gray, and total brain volume; and
applies a normalization factor to correct
for skull size (12). To avoid confounding
brain volume measurements because
not all scans included the full brain, the
SIENAX analyses were restricted to a pre-
speciﬁedintervalalongthez-axis,ranging
from 75 to 252 mm in standard MNI152
space. SIENAX is part of the FMRIB Soft-
ware Library (FSL). All SIENAX analyses
were performed using FSL version 2.6.
Total CBF was calculated from the
electrocardiographic-triggered two-
dimensional phase contrast images (TR
13 ms, TE 8.3 ms, FA 10°, FOV 150 mm,
128 3 88 acquisition matrix, 256 3 256
reconstruction matrix, slice thickness
5 mm, no slice gap, velocity sensitivity
140 cm/s) using the software package
FLOW (Leiden University Medical Cen-
ter, Leiden, the Netherlands). An experi-
enced researcher drew manual regions of
interestclosely aroundthevessellumenof
the internal carotid arteries and the basilar
artery(S.v.E.,3yearsofexperienceinneu-
roradiology). The ﬂow through the three
arteries was summed and multiplied by
theindividual’sheartrateduringMRscan-
ning tocalculate the tCBF (in mL/min). In
three subjects (two type 1 DM patients,
one healthy control) tCBF could not be
obtained due to incorrect positioning of
the phase-contrast imaging plane. Total
brain perfusion (in mL/min per 100 mL)
wasassessedbydividingtCBF(inmL/min)
by each individual’s total brain volume
(in mL) and multiplying the obtained re-
sult by 100.
For the evaluation of aortic stiffness,
aortic PWV was determined using a pre-
viously described protocol (14). In
short, a scout view of the aorta was per-
formed. Next, a velocity encoded image
perpendicular to the ascending aorta at
the level of the pulmonary trunk was as-
sessed. This resulted in through-plane
ﬂow measurements of the ascending and
proximal descendingaortaat thoselevels.
Linear regression between 20 and 80% of
therange betweendiastolicﬂow andpeak
systolic ﬂow determines the line follow-
ing the upstroke. Time point of intersec-
tion between the upstroke and the
baseline of the ﬂow curve was considered
being the arrival time of the foot of the
pulsewave.AorticPWVwassubsequently
calculatedfortheaortaasDx/Dt,whereDx
is the aortic path length between the two
measurement sites measured in the aortic
scout view and Dt is the time delay be-
tween the arrivals of the foot of the pulse
wave at the respective measurement sites.
Data were analyzed using MASS and
FLOW (Leiden University Medical Cen-
ter) by two observers (S.v.E. and A.B.,
both 4 years of experience in cardiac
MRI) supervised by a senior researcher
(J.W., 15 years of experience in cardiac
MRI).
Statistical analysis
Data are expressed as mean 6 SD. To
compare clinical characteristics between




iables were used. Kolmogorov-Smirnov
test showed that aortic PWV was nonnor-
mallydistributed(P, 0.001).Therefore,a
log transformation of aortic PWV values
was used in the analyses. To compare
MR ﬁndings between type 1 DM and
healthy control subjects, linear regression
analysis with covariates age, sex, and
MAP was applied.
In type 1 DM multivariable linear
regression analysis was performed to
study the association between brain vol-
umes and tCBF and aortic PWV, inde-
pendent of potential confounders deﬁned
as age, sex, MAP, BMI, smoking, heart
rate, DM duration, and HbA1c. P value
,0.05 was considered statistically signif-
icant. We used SPSS for Windows (ver-
sion16.0;SPSS,Chicago,IL)forstatistical
analysis.
RESULTS—The characteristics of the
studypopulationaredescribedinTable1.
Fifty-one type 1 DM patients (30 men,
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Vascular mechanisms of brain atrophy21 women, mean age 44 6 11 years,
mean type 1 DM duration 23 6 12 years)
and 34 healthy control subjects were in-
cluded. All type 1 DM patients were on
insulintreatment.Type1DMandhealthy
control subjects were comparable in age,
sex, BMI, systolic blood pressure, PP,
heart rate, current smokers, HDL choles-
terol, and creatinine. Type 1 DM patients
showed lower diastolic blood pressure
(P , 0.01), lower total cholesterol (P =
0.01), and lower triglyceride levels (P =
0.04). Twelve type 1 DM patients used
statins, whereas none of the healthy vol-
unteers did. One out of the 51 type 1 DM
patientsusedanACEinhibitorandanan-
giotensin II antagonist for the presence of
microalbuminuria. None of the type 1 DM
patients were on b-blocker use. None of
the volunteers used antihypertensive
medication.
WM brain volumes and GM brain
volumes, normalized for skull size, were
decreased in type 1 DM patients com-
pared with healthy control subjects (P =
0.04 for WM; respective P =0 . 0 3f o rG M
brain volume). Total brain perfusion was
signiﬁcantly increased in type 1 DM com-
pared with healthy control subjects pre-
senting with similar systolic blood
pressures and corrected for age, sex, and
MAP(b=20.219,P,0.05).AorticPWV
values were in the normal range in the
type 1 DM patient and healthy control
subjects (P = 0.21).
Table 2 shows the results of multivar-
iable linear regression analyses to assess
independent predictors for WM and GM
b r a i nv o l u m ei nt y p e1D M .B o t ht C B F
and aortic PWV were independent pre-
dictors of WM brain volume (b = 0.352,
P = 0.024 for tCBF; respective b =
20.458, P =0 . 0 1 6f o ra o r t i cP W V )i n
type 1 DM patients in a model including
covariates age, sex, MAP, BMI, smoking,
heart rate, DM duration, and HbA1c.I na
similar multivariable linear regression
model for GM brain volume, age was a
signiﬁcant predictor (b = 20.695, P ,
0.001) and tCBF and aortic PWV were
not. Both total CBF and aortic PWV did
not independently predict WM or GM
brainvolumesinhealthycontrolsubjects.
CONCLUSIONS—Thepurpose ofthe
current study was to assess the possible
association between brain volumes and
cerebral perfusion and aortic stiffness in
type 1 DM patients without hypertension
by using MRI. The main ﬁndings of our
studywere:1)type1DMpatientsshowed
WM and GM volume loss compared with
healthy control subjects concomitant
with a relative increased brain perfusion;
2) total CBF and stiffness of the aorta
independently predicted WM brain atro-
phy; and 3)agewastheonlyindependent
predictor of GM brain atrophy, whereas
tCBF and aortic PWV were not.
Our ﬁndings of cortical and subcor-
tical atrophy in type 1 DM are in line with
previous studies reporting mild cerebral
atrophy in type 1 DM compared with
control subjects (1,2). Furthermore, we
found concomitant hyperperfusion of
the brain. Impaired echo Doppler mea-
sured cerebrovascular reactivity has been
d e s c r i b e db e f o r ei nt y p e1D Mi na c -
cordance with our ﬁndings (9,15). The
Framingham heart study reported the
exposure of cardiovascular disease risk
factors, like DM, associated with high
resting arterial ﬂow and impaired vaso-
reactivity(16).Thevasodilatoryeffectof
persistent hyperinsulinemia was men-
tioned as a possible mechanism of the
high resting arterial blood ﬂow (17).
Furthermore, in our current study
tCBF and aortic stiffness were both pre-
dictors of WM brain atrophy. Recently,
two large cohort studies were the ﬁrst to
investigate and report associations be-
tween CBF and brain volumes (18,19).
An elevation in CBF, particularly in the
presence of factors that stiffen the aorta,
may allow additional pulsatility to pene-
trate into and damage the microcircula-
tion with subsequent cerebral tissue loss
(20,21). A similar mechanism is a well-
knownphenomenoninthekidneys;renal
Table 1—Clinical characteristics and MRI parameters of type 1 DM patients
and healthy control subjects
Type 1 DM patients
Healthy
control subjects P value
n 51 34 —
Characteristics
Age (years) 44 6 11 46 6 14 0.46
Men, n (%) 30 (59%) 17 (50%) 0.42
BMI (kg/m
2)2 5 . 0 6 3.2 26.2 6 3.9 0.18
Blood pressure (mmHg)
Systolic 126 6 18 128 6 15 0.62
Diastolic 74 6 10 80 6 11 ,0.01*
PP (mmHg) 52 6 13 47 6 13 0.11
MAP (mmHg) 91 6 11 96 6 11 0.04*
Heart rate (bpm) 65 6 10 61 6 10 0.05
Current smoker, n (%) 8 (16%) 2 (6%) 0.17
Retinopathy, no/minimal
background/laser treated 16/31/4
Peripheral neuropathy, n (%) 7 (14%)
Microalbuminuria, n (%) 4 (8%)
Laboratory markers
HbA1c (%) 7.6 6 1.0 NA NA
Fasting glucose level NA 4.9 6 0.6 NA
Cholesterol (mmol/L)
HDL 1.7 6 0.5 1.6 6 0.4 0.34
Total 4.7 6 0.9 5.3 6 1.2 0.01*
Triglycerides (mmol/L) 1.1 6 0.6 1.4 6 0.7 0.04*
Creatinine (mmol/L) 74 6 11 77 6 17 0.32
MRI ﬁndings
Aortic PWV (m/s) 5.3 (4.7–6.1) 5.7 (4.6–7.6) 0.21
tCBF (mL/min) 466 6 131 424 6 111 0.27
Total brain perfusion
(mL/min per 100 mL
brain tissue) 41.3 6 11.0 36.4 6 9.0 ,0.05†
Brain volume (mL)
WM 567 6 72 583 6 70 0.04†
GM 565 6 59 584 6 54 0.03†
Total 1,132 6 124 1,167 6 117 ,0.01†
*Signiﬁcantly different between groups using independent samples t test, P , 0.05. †Signiﬁcantly different
between groups, in multivariable linear regression analysis correcting for age, sex, and MAP, P , 0.05.
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van Elderen and Associateshyperperfusion is present in the earliest
stages of type 1 DM and considered to
contribute to renal injury and the pro-
gression to clinical nephropathy (22). It
has been suggested that the brain and the
kidneys, both high ﬂow organs with low
impedance vascular beds, present a com-
monanduniquevascularreactivitymech-
anism on blood pressure and ﬂow
ﬂuctuations.
We found aortic stiffness as an in-
dependent predictor of WM brain atro-
phy. To the best of our knowledge, no
studies investigated this relationship be-
fore. Measurements of aortic PWV repre-
sentpropagationspeedofthePP,whichis
inﬂuenced by both functional and struc-
turalchangesofthearterialvesselwall.An
earlier study found a positive correlation
between MR parameters of brain atrophy
and wall thickness of the internal carotid
artery aswellasadiagnosisofDMand the
current use of insulin in community-
dwelling elderly (3), which is in congru-
ence with our ﬁndings. Because vascular
resistance in the brain is very low, pulsa-
tions can extend well into the microvas-
cular cerebral bed. It is remarkable that
the aortic PWV was still in the normal
range without statistical signiﬁcant differ-
ence as compared with that in healthy
control subjects. We speculate that the
brain of type 1 DM patients may be sus-
ceptible to relative small changes in aortic
PWV, even when PWV appears to be rel-
ative normal. Moreover, aortic stiffness
may be a marker of arterial function and
inﬂammatory processes manifesting in
cerebral arteries and arterioles.
Of note, the association between aor-
tic PWV and WM brain volume was
found independent of tCBF, suggesting
two separate vascular mechanisms oper-
ating on WM brain atrophy.
The associations between WM brain
volumes and tCBF as well as aortic PWV
c o u l dn o tb es h o w nf o rG Mb r a i nv o l -
umes. It is known that the blood ﬂow in
the GM is substantially higher to the
amount of blood ﬂow in the WM because
of high metabolic activity in the GM (23).
Subtle ﬂu c t u a t i o ni na r t e r i a lb l o o dﬂow
or function may therefore spare GM
brain volume, in contrast with the vul-
nerable end-arterioles penetrating the
WM. An earlier study suggested that
persistent hyperglycemia and acute se-
vere hypoglycemic events have an im-
pact on early subtle alterations in GM
s t r u c t u r ei nt y p e1D Mp a t i e n t s( 2 4 ) .I n
our study age was the only and strong
predictorof GM brain atrophy, conﬁrm-
ing the theory of accelerated brain aging
in DM.
This study has some limitations. Our
study design does not allow revealing the
exact (complex) mechanisms by which
increased cerebralbloodﬂow and normal
values of aortic PWV affect WM brain
volume in type 1 DM. Both a direct
detrimentalpulsatileeffectonthecerebral
microcirculation as well as impaired vas-
cular compensatory mechanisms during
conditions such as hypoglycemia, hypo-
tension, and hypoxia may be involved in
tissue loss of the vulnerable diabetic brain
(6). Second, involvement of autonomic
neuropathy can be assumed for the pres-
ence of cerebral hyperperfusion accord-
ing to the (nonsigniﬁcant) higher heart
rate in our type 1 DM patients. Future
studies areneededtoexplore these mech-
anisms.
Our results may have important im-
plications. First, our study results reveal
further insight into the pathophysiology
of brain atrophy in type 1 DM. Our
ﬁndings suggest two separate vascular
mechanisms, namely tCBF and aortic
stiffness, being involved in WM brain
atrophy in type 1 DM patients, indepen-
dent of glucose regulation. Second, our
ﬁndings may have prognostic implica-
tions. Assessment of aortic PWV may
have prognostic implications, even when
values fall into the normal range, possibly
due to increased brain susceptibility in
DM patients. Furthermore, the arterial
system is known to stiffen with older age
and high blood pressure (25). When pa-
tients with type 1 DM become older or
develop hypertension, increased aortic
stiffening may occur with subsequent ad-
verse changes in WM brain volumes. On
the other hand, methods likely to detect
subtle changes in the brain are essential
for evaluating the effects of type 1 DM on
the brain since the gradual progress of ce-
rebralchangesmaymakethemdifﬁcultto
detectuntilyearsafteronsetoftype1DM.
Earlier detection of brain structural
changes may increase the likelihood that
treatment interventions can slow down
the progression of these impairments.
However, longitudinal studies are re-
quired to conﬁrm our results and to in-
vestigate the clinical implications of our
ﬁndings.
In conclusion, type 1 DM patients
without hypertension showed WM and
GM volume loss compared with healthy
control subjects concomitant with a rela-
tive increased brain perfusion. Total CBF
and stiffness of the aorta independently
predicted WM brain atrophy in type 1
DM patients. Only age predicted GM
brain atrophy. Future prospective studies
are needed to assess the prognostic and
clinical implications of these initial ob-
servations.
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Table 2—Results of multivariable linear regression analyses performed in type 1 DM
patients to assess independent predictors of WM and, respectively, GM brain volumes
Brain volume
WM GM
b P value b P value
Age (years) 0.13 0.56 20.70 ,0.001
Men (n =3 0 ) 20.27 0.06 0.14 0.21
MAP (mmHg) 20.04 0.80 20.10 0.45
BMI (kg/m
2) 0.20 0.15 20.03 0.77
Smoking, yes (n = 8) 0.06 0.68 0.12 0.28
DM duration (years) 20.18 0.35 0.02 0.91
HbA1c (%) 20.04 0.83 0.23 0.08
Aortic PWV (m/s) 20.46 0.02 0.07 0.62
tCBF (mL/min) 0.35 0.02 0.11 0.36
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